Ricevi le ultime notizie sulle azioni Azitra con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di AZTR

Ultime notizie per

Anitra

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Azitra Inc

Press Releases

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Stock Split

Azitra, Inc. Announces Reverse Stock Split

Earnings

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Azitra Receives Notice of Non-Compliance from NYSE American

Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit

AZTR

Aditxt

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

bioAffinity Technologies

Celularity

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Comments

Azitra Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO